ENDRA Life Sciences Inc (NDRA): רווח נקי למניה ב-12 החודשים האחרונים

The potential for mass steatosis screening via the accessible TAEUS system promises active growth, which the GURU.Markets terminal reflects through a rolling revenue per share metric, where the value -6.29 represents the latest figure. ENDRA Life Sciences (NDRA) bases its success on synergy with ultrasound scanner manufacturers, while patent protection for thermoacoustics and strict regulatory oversight create a significant barrier to entry for new players.

The search for sustainable assets begins with an analysis of the real return on capital. Earnings per share (EPS TTM) measures the portion of profit allocated to each ordinary share over a year, excluding the impact of the total issuance volume. For ENDRA Life Sciences (NDRA), this calculation is critical due to the lack of profit and the costs associated with bringing diagnostic systems to market. The risk of regulatory delays makes the 12-month rolling EPS history an indicator of financial vulnerability. Analyzing this curve allows for the timely identification of a correction phase.